1. Marchetti P., Coppelli A., R. Giannarelli. Pathophysiological links between diabetes and heart disease // Medicographia. - 2007. - Vol. 29, № 3. - P. 213-219.
3. Kannel W.B., Wolf P.A., Benjamin E.J., Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates // Am. J. Cardiol. - 1998. - Vol. 82, № 8A. - P. 2N-9N.
5. Wild S., Wild S., Roglic G., Green A., Sicree R., King H. Global prevalence of diabetes; estimates for year 2000 and projections for 2030 // Diabetes Care. - 2004. - Vol. 27, № 5. - P. 1047-1053.
7. Amar J. Patients with resistant hypertension // J. Hypertens. - 2007. - Vol. 25, № 1. - P. S3-S6.
9. Карпов Ю.А. Артериальная гипертония у больных сахарным диабетом: основные направления лечения // Метаболический синдром. - 2001. - Т. 9, № 24. - С. 1132-1136. 6.
11. Diabetes Atlas, 3rd edition. International Diabetes Federation, 2006. - 220 р. 6.
13. International Diabetes Federation: Diabetes Atlas third edition / J. Hypertens. - 2001. - № 19. - P. 1167-1176. - [http://www.eatlas.idf.org/media/2006] [Electronic].
15. Кактурский Л.В. Внезапная сердечная смерть: современное состояние проблемы // Арх. патологии. - 2005. - Т. 67. - С. 8-11.
17. Kаntachuvessiri A. Pulmonary veins: Preferred site for catheter ablation of atrial fibrillation // Heart and Lung. - 2002. - Vol. 31, № 4. - P. 271-278.
19. Prystupa A., Łopatyński J., Mieczkowska J. Atrial fibrillation and its association with type 2 diabetes // Ann. Universitat is Mariae Curie - Skłodowska. - 2008. - Vol. LXIII, № 2, 9. - P. 53-57.
21. Kannel W.B., Benjamin E.J. Status of the epidemiology of atrial fibrillation // Med. Clin. North. Am. - 2008. - Vol. 92, № 1. - P. 17-40.
23. Healey J.S., Connolly S.J. Atrial fibrillation: hypertension as a causative agent, risk factor for complications, and potential therapeutic target // Am. J. Cardiol. - 2003. - Vol. 91, № 10A. - P. 9G-14G.
25. Weber K.T. Targeting pathological remodeling: concepts of cardioprotection and reparation // Circulation. - 2000. - Vol. 102, № 12. - P. 1342-1345.
27. Verdecchia P., Reboldi G <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Reboldi%20G%22%5BAuthor%5D>., Gattobigio R <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Gattobigio%20R%22%5BAuthor%5D>. et al. Atrial fibrillation in hypertension: predictors and outcome // Hypertension. - 2003. - Vol. 41, № 2. - P. 218-223.
29. Ciaroni S., Cuenoud L., Bloch A. Clinical study to investigate the predictive parameters for the onset of atrial fibrillation in patients with essential hypertension // Am. Heart. J. - 2000. - Vol. 139, № 5. - P. 814-819.
31. Krahn A.D., Manfreda J., Tate R.B., Mathewson F.A., Cuddy T.E. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba follow-up study // Am. J. Med. - 1995. - Vol. 98, № 5. - P. 476-484.
33. Wachtell K., Lehto M., Gerdts E. et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study // J. Am. Coll. Cardiol. - 2005. - Vol. 45, № 5. - P. 712-719.
35. Du X., Ninomiya T., de Galan B. et al. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study // Eur. Heart. J. - 2009. - Vol. 30, № 9. - P. 1128-1135.
37. Свеклина Т.С. и др. Лабораторные маркеры кардиоваскулярного прогноза у пациентов с артериальной гипертензией в сочетании с сахарным диабетом второго типа и фибрилляцией предсердий // Вестн. Чувашского государственного педагогического ун-та им. И.Я. Яковлева. - 2010. - Т. 68, № 4. - С. 12-18.
39. Pearlman N.W., Meyers A.D., Sullivan W.G. Muscle fiber orientation and connective tissue content in the hypertrophied human heart // Lab. Invest. - 1982. - Vol. 46, № 2. - P. 158-164.
41. Border W.A., Noble N.A. Transforming growth factor beta in tissue fibrosis // N. Engl. J. Med. - 1994. - Vol. 331, № 19. - P. 1286-1292.
43. Lorell B.H., Carabello B.A. Left ventricular hypertrophy: pathogenesis, detection, and prognosis // Circulation. - 2000. - Vol. 102, № 4. - P. 470-479.
45. Gerdts E., Oikarinen L., Palmieri V. et al. Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study // Hypertension. - 2002. - Vol. 39, № 3. - P. 739-743.
47. Psaty B.M., Manolio T.A., Kuller L.H. et al. Incidence of and risk factors for atrial fibrillation in older adults // Circulation. - 1997. - Vol. 96, № 7. - P. 2455-2461.
49. Mattioli A.V., Vivoli D., Bastia E. Doppler echocardiography parameters predictive of recurrence of atrial fibrillation of different etiologic origins // J. Ultrasound. Med. - 1997. - № 16. - P. 695-698.
51. Madu E.C., Baugh D.S <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Baugh%20DS%22%5BAuthor%5D>., Gbadebo T.D <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Gbadebo%20TD%22%5BAuthor%5D>. Effect of ethnicity and hypertension on atrial conduction: evaluation with high-resolution P-wave signal averaging // Clin. Cardiol. - 2001. - Vol. 24, № 9. - P. 597-602.
53. Maggioni A.P., Latini R <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Latini%20R%22%5BAuthor%5D>., Carson P.E <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Carson%20PE%22%5BAuthor%5D>. et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT) // Am. Heart. J. - 2005. - Vol. 149, № 3. - P. 548-557.
55. Adler A.I., Stratton I.M., Neil H.A. et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study // Br. Med. J. - 2000. - Vol. 321, № 7258. - P. 412-419.
57. Shi Y., Li D <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Li%20D%22%5BAuthor%5D>., Tardif J.C <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Tardif%20JC%22%5BAuthor%5D>., Nattel S <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Nattel%20S%22%5BAuthor%5D>. Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure // Cardiovasc. Res. - 2002. - Vol. 54, № 2. - P. 456-461.
59. Everett T.H. 4th, Li H <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Li%20H%22%5BAuthor%5D>., Mangrum J.M <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Mangrum%20JM%22%5BAuthor%5D>. et al. Electrical, morphological, and ultrastructural remodeling and reverse remodeling in a canine model of chronic atrial fibrillation // Circulation. - 2000. - Vol. 102, № 12. - P. 1454-1460.
61. Allessie M.A. Atrial electrophysiologic remodeling: another vicious circle? // J. Cardiovasc. Electrophysiol. - 1998. - Vol. 9, № 12. - P. 1378-1393.
63. Goette A., Staack T <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Staack%20T%22%5BAuthor%5D>., Rцcken C <http://www.ncbi.nlm.nih.gov/pubmed?term=%22R%C3%B6cken%20C%22%5BAuthor%5D>. et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation // J. Am. Coll. Cardiol. - 2000. - Vol. 35, № 6. - P. 1669-1677.
65. Klein H.U., Goette A. Blockade of atrial angiotensin II type 1 receptors: a novel antiarrhythmic strategy to prevent atrial fibrillation? // J. Am. Coll. Cardiol. - 2003. - Vol. 41, № 12. - P. 2205-2206.
67. Аметов А.С., Демидова Т.Ю., Галиева О.Р. Ингибиторы ангиотензинпревращающего фермента в профилактике и лечении сосудистых осложнений сахарного диабета // Кардиология. - 2005. - Т. 45, № 11. - С. 109-112.
69. Nilsson P., Lindholm L., Scherstén B. Hyperinsulinaemia and other metabolic disturbances in well-controlled hypertensive men and women: an epidemiological study // J. Hypertens. - 1990. - Vol. 8, № 10. - P. 953-959. 36.
71. American Diabetes Association. Standards of medical care in diabetes: 2006 // Diabetes Care. - 2006. - Vol. 29 (Suppl. 1), № 11. - Р. S4-S42.
73. Estasio R.O., Jeffers B.W., Hiatt W.R. et al. The effect of nisoldipine as compared with noninsulin-dependent diabetes and hypertension // N. Engl. J. Med. - 1998. - Vol. 338, № 10. - P. 645-652. 38.
75. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular complications in type 2 diabetes: UKPDS 38 // Br. Med. J. - 1998. - Vol. 317, № 7160. - P. 703-713.
77. Tuomilehto J., Rastenyte D <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Rastenyte%20D%22%5BAuthor%5D>., Birkenhдger W.H <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Birkenh%C3%A4ger%20WH%22%5BAuthor%5D>. et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension // N. Engl. J. Med. - 1999. - Vol. 340, № 9. - P. 677-684.
79. Lievre M., Gueyffier F <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Gueyffier%20F%22%5BAuthor%5D>., Ekbom T <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Ekbom%20T%22%5BAuthor%5D>. et al. Efficacy of diuretics and beta-blockers in diabetic hypertensive patients: results from meta-analysis // Diabetes Care. - 2000. - Vol. 23 (Suppl. 2). - P. B56-B71. 41.
81. PROGRESS Collaborative Group. Randomized trial of perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke and transient ischemic attack / Lancet. - 2001. - Vol. 358, № 9287. - P. 1033-1041. 42.
83. ACCORD Study Group, Cushman W.C., Evans G.W., Byington R.P. et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus // N. Engl. J. Med. - 2010. - Vol. 362, № 17. - P. 1575-1585.
85. Pessina A.C. Target organs of individuals with diabetes caught between atrial stiffness and damage to the microcirculation // J. Hypertens. - 2007. - Vol. 25, № 1. - P. S13-S17.
87. El-Atat F.A., McFarlane S.I., Sowers J.R. Diabetes, hypertension and cardiovascular derangements: Update on the pathophysiology and management // Curr. Hypertens. Rep. - 2004. - Vol. 6, № 3. - P. 215-223.
89. Chen J., Muntner P., Hamm L.L. et al. The metabolic syndrome and chronic kidney disease in US Adults // Ann. Intern. Med. - 2004. - Vol. 140, № 3. - P. 167-175.
91. McFarlane S.I., Banerji M., Sowers J.R. Insulin resistance and cardiovascular disease // J. Clin. Endocrinol. Metab. - 2001. - Vol. 86, № 2. - P. 713-718.
93. Mancia G., Bombelli M <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Bombelli%20M%22%5BAuthor%5D>., Corrao G <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Corrao%20G%22%5BAuthor%5D>. et al. Metabolic syndrome in the Pressioni Arteriose Monitorate E Lolo Associazioni (PAMELA) study: daily life blood pressure, cardiac damage and prognosis // Hypertension. - 2007. - Vol. 49, № 1. - P. 40-47.
95. Kendall D.M., Sobel B.E., Coulston A.M. et al. The insulin resistance syndrome and coronary artery disease // Coron. Artery Dis. - 2003. - Vol. 14, № 4. - P. 335-348.
97. Sowers J.R. Insulin resistance and hypertension // Am. J. Physiol. Heart Circ. Physiol. - 2004. - Vol. 286, № 5. - P. H1597-1602.
99. Ferrannini E., Buzzigoli G., Bonadonna R. et al. Insulin resistance in essential hypertension // N. Engl. J. Med. - 1987. - Vol. 317, № 6. - P. 350-357.
101. Govindarajan G. et al. Obesity and hypertension: A clinical update // Molecular mechanisms in hypertension / Ed. by R. Ray, E. Schiffrin, J.R. Sowers. - London: Taylor and Francis Pub, 2006. - P. 397-406.
103. Baron A.D. Insulin and the vasculature - old actors, new roles // J. Invest. Med. - 1996. - Vol. 44, № 8. - P. 406-412.
105. Tooke J.E., Hannemann M.M. Adverse endothelial function and the insulin resistance syndrome // J. Intern. Med. - 2000. - Vol. 247, № 4. - P. 425-431.
107. Banos G., Carvajal K., Cardoso G., Zamora J., Franco M. Vascular reactivity and effect of serum in a rat model of hypertriglyceridemia and hypertension // Am. J. Hypertens. - 1997. - Vol. 10, № 4, Pt. 1. - P. 379-388.
109. Tripathy D., Mohanty P., Dhindsa S. et al. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects // Diabetes. - 2003. - Vol. 52, № 12. - P. 2882-2887.
111. Heeringa J., van der Kuip D.A., Hofman A. et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study // Eur. Heart. J. - 2006. - Vol. 27, № 8. - P. 949-953.
113. Wanahita N., Messerli F.H., Bangalore S., Gami A.S., Somers V.K., Steinberg J.S. Atrial fibrillation and obesity - results of a meta-analysis // Am. Heart. J. - 2008. - Vol. 155, № 2. - P. 310-315.
115. Movahed M.R., Hashemzadeh M., Jamal M.M. Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease // Int. J. Cardiol. - 2005. - Vol. 105, № 3. - P. 315-318.
117. Korantzopoulos P., Kokkoris S., Kountouris E., Protopsaltis I., Siogas K., Melidonis A. Regression of paroxysmal atrial fibrillation associated with thiazolidinedione therapy // Int. J. Cardiol. - 2008. - Vol. 125, № 3. - P. e51-e53.
119. Johansen O.E., Brustad E., Enger S., Tveit A. Prevalence of abnormal glucose metabolism in atrial fibrillation: A case control study in 75-year old subjects // Cardiovasc. Diabetol. - 2008. - № 7. - P. 28.
121. Barriales A.V., Morís de la Tassa C., Sánchez Posada I. et al. The etiology and associated risk factors in sample of 300 patients with atrial fibrillation // Rev. Esp. Cardiol. - 1999. - Vol. 52, № 6. - P. 403.
123. Kato T., Ishida S., Morooka T. et al. Postprandial hyperglycemia is a possible contributor to paroxysmal atrial fibrillation: a case report // J. Cardiol. - 2006. - Vol. 48, № 5. - P. 269-272.
125. Chung M.K., Martin D.O., Sprecher D. et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation // Circulation. - 2001. - Vol. 104, № 24. - P. 2886-2891.